ME01555B - FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA - Google Patents

FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA

Info

Publication number
ME01555B
ME01555B MEP-2013-137A MEP13713A ME01555B ME 01555 B ME01555 B ME 01555B ME P13713 A MEP13713 A ME P13713A ME 01555 B ME01555 B ME 01555B
Authority
ME
Montenegro
Prior art keywords
ethoxybenzyl
glucitol
metformin
thio
methylphenyl
Prior art date
Application number
MEP-2013-137A
Other languages
English (en)
Inventor
Teisuke Takahashi
Saeko Uchida
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of ME01555B publication Critical patent/ME01555B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Predmetni pronalazak se odnosi na farmaceutske preparate koji su korisni u lečenju dijabetes melitusa, bolesti koje se dovode u vezu sa dijabetesom melitusom ili komplikacija dijabetesa melitusa, i to na  farmaceutske preparate koji sadrže kombinaciju (A) (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-D-glucitola ili njegove farmaceutski prihvatljive soli ili hidrata takvog jedinjenja ili soli; i (B) metformina.
MEP-2013-137A 2009-04-16 2010-04-16 FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA ME01555B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
EP10764570.7A EP2419097B1 (en) 2009-04-16 2010-04-16 Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
PCT/JP2010/057196 WO2010119990A1 (en) 2009-04-16 2010-04-16 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ME01555B true ME01555B (me) 2014-04-20

Family

ID=42982643

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2013-137A ME01555B (me) 2009-04-16 2010-04-16 FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA
MEP-2015-6A ME02015B (me) 2009-04-16 2010-04-16 Farmaceutski preparati sa (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi- 4-metilfenil]-1-tio-D-glucitolom i sekretagogom insulina

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2015-6A ME02015B (me) 2009-04-16 2010-04-16 Farmaceutski preparati sa (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi- 4-metilfenil]-1-tio-D-glucitolom i sekretagogom insulina

Country Status (30)

Country Link
US (1) US20120040898A1 (me)
EP (3) EP2601949B1 (me)
JP (4) JP5077786B2 (me)
KR (2) KR20150046382A (me)
CN (7) CN102395364A (me)
AR (1) AR076317A1 (me)
AU (1) AU2010237748B2 (me)
BR (1) BRPI1012539A2 (me)
CA (1) CA2755392A1 (me)
CY (2) CY1114703T1 (me)
DK (2) DK2419097T3 (me)
ES (2) ES2431300T3 (me)
HK (6) HK1217302A1 (me)
HR (2) HRP20131120T1 (me)
ME (2) ME01555B (me)
MX (1) MX2011010901A (me)
MY (3) MY156679A (me)
NZ (4) NZ710575A (me)
PH (3) PH12015500235A1 (me)
PL (2) PL2419097T3 (me)
PT (2) PT2601949E (me)
RS (2) RS53056B (me)
RU (2) RU2532330C2 (me)
SG (6) SG2014012553A (me)
SI (2) SI2419097T1 (me)
SM (1) SMT201500015B (me)
TW (3) TW201622720A (me)
UA (2) UA111742C2 (me)
WO (1) WO2010119990A1 (me)
ZA (1) ZA201106727B (me)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
IN2012DN02751A (me) 2009-09-30 2015-09-18 Boehringer Ingelheim Int
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6234443B2 (ja) 2012-05-17 2017-11-22 ブイティーブイ・セラピューティクス・エルエルシー 糖尿病治療のためのグルコキナーゼ活性化因子組成物
CN104780942A (zh) * 2012-08-30 2015-07-15 大正制药株式会社 Sglt2抑制剂和抗高血压药的组合
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR102309654B1 (ko) 2013-04-18 2021-10-08 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
SG11201707008SA (en) * 2015-02-27 2017-09-28 Asan Found Composition for preventing or treating valve calcification, containing dpp-4 inhibitor
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
US20210212968A1 (en) 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
US11439689B2 (en) * 2016-11-14 2022-09-13 Kaohsiung Medical University Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
AU2002254567B2 (en) * 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
CA2655937A1 (en) * 2006-06-29 2008-01-03 Taisho Pharmaceutical Co., Ltd. C-phenyl 1-thioglucitol compound
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
EP2054426A1 (en) * 2006-08-15 2009-05-06 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
WO2008055940A2 (en) * 2006-11-09 2008-05-15 Boehringer Ingelheim International Gmbh Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
EP2103607A4 (en) * 2006-12-14 2011-01-05 Taisho Pharmaceutical Co Ltd 1-phenyl-1-thio-D-GLUCITOLDERIVAT
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo

Also Published As

Publication number Publication date
SG2014014807A (en) 2014-05-29
EP2419097B1 (en) 2013-09-25
EP2601949B1 (en) 2014-10-29
SG2014012405A (en) 2014-05-29
EP2829271A3 (en) 2015-05-27
US20120040898A1 (en) 2012-02-16
HK1218871A1 (zh) 2017-03-17
JP5660094B2 (ja) 2015-01-28
NZ710575A (en) 2016-06-24
HK1217301A1 (zh) 2017-01-06
HRP20131120T1 (hr) 2013-12-20
NZ606888A (en) 2014-07-25
PL2601949T3 (pl) 2015-04-30
MY182720A (en) 2021-02-03
CN105477639A (zh) 2016-04-13
UA105216C2 (en) 2014-04-25
ZA201106727B (en) 2012-11-28
EP2601949A2 (en) 2013-06-12
JP5077786B2 (ja) 2012-11-21
NZ595314A (en) 2013-03-28
JP6066144B2 (ja) 2017-01-25
JP2015063543A (ja) 2015-04-09
PH12019500959B1 (en) 2020-06-29
NZ623838A (en) 2015-09-25
EP2419097A1 (en) 2012-02-22
TW201500043A (zh) 2015-01-01
PH12019500961A1 (en) 2020-08-03
RU2011146335A (ru) 2013-05-27
EP2829271A2 (en) 2015-01-28
HRP20141080T1 (hr) 2015-01-02
MY183793A (en) 2021-03-16
BRPI1012539A2 (pt) 2016-03-29
SG2014012553A (en) 2014-05-29
RU2532330C2 (ru) 2014-11-10
MY156679A (en) 2016-03-15
PH12019500959A1 (en) 2020-06-29
SG175154A1 (en) 2011-11-28
DK2419097T3 (da) 2013-10-28
SMT201500015B (it) 2015-03-05
EP2601949A3 (en) 2013-09-18
ES2523408T3 (es) 2014-11-25
JP2013006854A (ja) 2013-01-10
SG2014015093A (en) 2014-04-28
CY1115907T1 (el) 2017-01-25
CN105343880A (zh) 2016-02-24
PT2601949E (pt) 2014-11-12
CY1114703T1 (el) 2016-10-05
HK1217302A1 (zh) 2017-01-06
JP2016104775A (ja) 2016-06-09
ES2431300T3 (es) 2013-11-25
CN105343059A (zh) 2016-02-24
AU2010237748B2 (en) 2014-10-30
PL2419097T3 (pl) 2014-02-28
TW201622720A (zh) 2016-07-01
RS53056B (en) 2014-04-30
PH12015500235B1 (en) 2015-12-02
CN105343871A (zh) 2016-02-24
DK2601949T3 (da) 2015-01-05
WO2010119990A1 (en) 2010-10-21
EP2419097A4 (en) 2012-09-05
AU2010237748A1 (en) 2011-10-20
UA111742C2 (uk) 2016-06-10
PH12015500235A1 (en) 2015-12-02
SG2014012462A (en) 2014-05-29
CN105434430A (zh) 2016-03-30
PH12019500961B1 (en) 2020-08-03
RS53761B1 (en) 2015-06-30
AR076317A1 (es) 2011-06-01
TW201103534A (en) 2011-02-01
JP5910711B2 (ja) 2016-04-27
PT2419097E (pt) 2013-10-03
ME02015B (me) 2015-05-20
CN102395364A (zh) 2012-03-28
MX2011010901A (es) 2011-11-01
CN105343060A (zh) 2016-02-24
HK1218881A1 (zh) 2017-03-17
JP2012524710A (ja) 2012-10-18
KR20150046382A (ko) 2015-04-29
HK1217434A1 (zh) 2017-01-13
HK1217435A1 (zh) 2017-01-13
SI2601949T1 (sl) 2014-12-31
KR20120016051A (ko) 2012-02-22
SI2419097T1 (sl) 2014-01-31
CA2755392A1 (en) 2010-10-21
RU2014121260A (ru) 2015-12-10

Similar Documents

Publication Publication Date Title
ME01555B (me) FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2008000592A1 (es) Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
NO20084924L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
TW200833330A (en) Substituted dihydropyrazolones and their use
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
EA201201623A1 (ru) Лечение диабета 2 типа
WO2007130825A3 (en) Fused heterocyclic compounds and their use as mglur5 modulators
CL2007001530A1 (es) Compuestos derivados de tiazol, inhibidores de fbpasa; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de diabetes mellitus tipo i, ii y iii, desequilibrio de glucosa en ayunas, desequilibrio en la tolerancia de la glucosa y complicaciones de la diabetes.
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
DE602007014206D1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
WO2008098985A3 (en) Pharmaceutical composition for the treatment of il-8 mediated diseases
CL2008003546A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii.
NO20074536L (no) Anvendelse av jern (III)-komplekssammensetninger
NO20075752L (no) Kimeriske proteiner, deres fremstilling og farmasoytiske sammensetninger som inneholder dem
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
WO2006129160A3 (en) Stable aqueous oral solution of risperidone